| Outcome Measures: |
Primary: Change in histological Grade as evaluated with Non-alcoholic Steatohepatitis Clinical Research Network Scoring System, liver biopsy, baseline, 6 months|Change in serum FGF 21, blood test, baseline and 6 months | Secondary: Change in fibroscan and elastography measure of liver stiffness, imaging, baseline and 6 months|Change in Liver enzymes, blood test - AST,ALT, gamma GT, baseline and 6 months|Change in steatosis, histological, baseline and 6 months|Change in lobular inflammation, histological, baseline and 6 months|Change in ballooning, histological, baseline and 6 months|Change in fibrosis, histological, baseline and 6 months|Change in metabolic outcome -HbA1c, serum concentration, baseline and 6 months|Change in metabolic outcome - fasting NEFA, serum concentration, baseline and 6 months|Change in metabolic outcome - fasting Tg, serum concentration, baseline and 6 months|Change in serum FGF 19, serum concentration, baseline and 6 months|Change in serum adiponectin, serum concentration, baseline and 6 months|Change in serum IL-6, serum concentration, baseline and 6 months|Change in serum TNF alpha, serum concentration, baseline and 6 months|Change in serum uric acid, serum concentration, baseline and 6 months|Change in MRI features of NASH, serum concentration, baseline and 6 months
|
